drugset / Trial / NCT02595437

Triferic Pediatric Pharmacokinetic Protocol

NCT02595437

Phase 1/2 Completed 22 enrolled Rockwell Medical Technologies, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.

Timeline

Start
2015-11-01
Primary completion
2016-12
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Triferic Other / unclassified 0.07 mg/kg Intravenous